Pre-Clinical & Clinical Data Supporting Development of ENaBL: A Nanobody-Targeted, Immune-Shielded Lentiviral Platform for In-Vivo Cell Reprogramming
- Key preclinical data supporting the engineered features of the ENaBL vector for T-cell reprogramming
- Present clinical data demonstrating the safety and efficiency of ENaBL’s in-vivo BCMA CAR-T reprogramming in patients with multiple myeloma
- Highlight key clinical outcomes on response rates, persistence, and safety profile compared to ex-vivo approaches